Independent Data and Safety Monitoring Board Recommends Unblinding Study Participants
DURHAM, N.C. – Engaging disenfranchised men who have sex with men (MSM) living with HIV in the U.S. is possible, but the best way to help them achieve and maintain viral suppression is not yet known, according to findings from HPTN 078 being reported today at the 10th IAS Conference on HIV Science (IAS 2019) in Mexico City.
DURHAM, NC – Researchers today presented results from the HPTN 071 (PopART) study at the annual Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
DURHAM, NC – Researchers from the HIV Prevention Trials Network (HPTN) today presented results from the HPTN 075 Study at the HIV Research for Prevention (HIVR4P) conference in Madrid, Spain. The study evaluated the feasibility of HIV prevention research among men who have sex with men (MSM) and transgender women (TGW) in three countries in sub-Saharan Africa. Findings from the study showed participants were at an alarming risk for getting HIV.
The HIV Prevention Trials Network (HPTN) congratulates the participants and researchers taking part in two important HIV prevention trials announcing results this week at the AIDS 2018 conference – the Sustainable East Africa Research in Community Health (SEARCH) study and the Botswana Combination Prevention Project (BCPP) study. Both studies were cluster-randomized, community-based trials conducted in sub-Saharan Africa that measured the impact of enhanced HIV services and the offer of universal treatment on HIV incidence.
DURHAM, N.C. – The HIV Prevention Trials Network (HPTN) today announced the initiation of HPTN 084, a Phase 3 double-blind safety and efficacy study of long-acting injectable cabotegravir (CAB) compared to a combination of daily oral tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg (TDF/FTC).
DURHAM, N.C. – Study results released today by the HIV Prevention Trials Network (HPTN) show long-acting injectable cabotegravir (CAB LA) to be well tolerated by men and women and support the dosing schedule currently being used in a phase 3 HPTN study for HIV prevention. Analysis of HPTN 077 study data presented today at the 9th IAS Conference on HIV Science in Paris, France, supported further development of CAB LA for HIV prevention in men and women using 600mg (3 mL) injections every eight weeks with the first two injections given four weeks apart.
DURHAM, N.C. - The HPTN 065 study, conducted by the HIV Prevention Trials Network (HPTN), showed that financial incentives can motivate some people living with HIV (PLWH) to take their HIV antiretroviral therapy (ART) medication regularly and maintain viral load suppression. This finding could have implications for improving health outcomes and decreasing the risk of transmitting the virus to others. Study findings were published today in JAMA Internal Medicine.
DURHAM, N.C. – The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC). If found to be safe and effective for HIV pre-exposure prophylaxis, also known as PrEP, injectable CAB may be easier for some people to adhere to than daily oral TDF/FTC.
The HIV Prevention Trials Network (HPTN) commends the participants and researchers on successful completion of the ANRS 12249 TasP (Treatment as Prevention) Study. The study was conducted in a rural area of northern KwaZulu-Natal (South Africa) where HIV incidence was compared between communities randomized to either immediate offer of antiretroviral therapy (ART) for all individuals diagnosed with HIV, or standard of care ART initiation. Both study arms included home-based HIV testing.
DURBAN, South Africa and DURHAM, N.C. – Investigators from the HIV Prevention Trials Network (HPTN) today announced key results from the HPTN 073 Study at the International AIDS Conference (AIDS 2016) in Durban, South Africa. The study, which assessed uptake and adherence of oral pre-exposure prophylaxis (PrEP) for the prevention of HIV infection among Black men who have sex with men (BMSM) in the U.S., demonstrated consistency between self-report and biological markers of adherence.
DURHAM, N.C. – The HIV Prevention Trials Network (HPTN) announced today that the final results of the HPTN 052 study were published in the New England Journal of Medicine (NEJM). This pivotal study demonstrated that antiretroviral therapy (ART) for HIV infection provides durable and reliable protection against the sexual transmission of the virus from infected men and women to their HIV-uninfected sexual partners.
First Study to Evaluate Efficacy of Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among At Risk Populations